Species independence in brain tissue binding using brain homogenates

Drug Metabolism and Disposition

Volumn 39, Issue 7, 2011, Pages 1270-1277

  Di, Li ^a   Umland, John P ^a   Chang, George ^a   Huang, Youping ^a   Lin, Zhen ^a   Scott, Dennis O ^a   Troutman, Matthew D ^a   Liston, Theodore E ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; AMFEBUTAMONE; APREPITANT; ARIPIPRAZOLE; AZELASTINE; BROMOCRIPTINE; BUPIVACAINE; BUSPIRONE; CARBAMAZEPINE; CHLORPROMAZINE; CITALOPRAM; CLINAFLOXACIN; DESIPRAMINE; DONEPEZIL; INDOMETACIN; LIDOCAINE; NIMODIPINE; NORTRIPTYLINE; PALIPERIDONE; PAROXETINE; PHENYTOIN; RIFAMPICIN; RILUZOLE; RITONAVIR; RIVASTIGMINE; TALINOLOL; TELMISARTAN; TERODILINE; TRAZODONE; UNINDEXED DRUG;

ANIMAL TISSUE; ARTICLE; BEAGLE; BRAIN HOMOGENATE; BRAIN TISSUE; CD1 MOUSE; CONTROLLED STUDY; CYNOMOLGUS MONKEY; DOG; GUINEA PIG; HARTLEY GUINEA PIG; HUMAN; HUMAN TISSUE; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; RAT; SPECIES DIFFERENCE; SPRAGUE DAWLEY RAT; SWINE; TISSUE STRUCTURE; WISTAR HANNOVER RAT;

ANIMALS; BRAIN; DOGS; GUINEA PIGS; HUMANS; MACACA FASCICULARIS; MICE; RATS; SPECIES SPECIFICITY;

CANIS FAMILIARIS; CAVIA; MACACA FASCICULARIS; RATTUS;

EID: 79959417881     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.111.038778     Document Type: Article

References (37)

1. Becker S and Liu X (2006) Evaluation of the utility of brain slice methods to study brain penetration. Drug Metab Dispos 34:855-861.
2. Brighty KE, Guhan SS, Jefson MR, Linde RG II, and McCormick EL (1999) inventors; Pfizer Products, Inc., assignee. Hygromycin A derivatives. World patent WO 9957125. 1999 November 11.
3. de Lange EC, Danhof M, de Boer AG, and Breimer DD (1997) Methodological considerations of intracerebral microdialysis in pharmacokinetic studies on drug transport across the bloodbrain barrier. Brain Res Rev 25:27-49. (Pubitemid 27459719)
4. Deur C, Agrawal AK, Baum H, Booth J, Bove S, Brieland J, Bunker A, Connolly C, Cornicelli J, Dumin J, et al. (2007) N-(6,7-Dichloro-2,3-dioxo-1,2, 3,4-tetrahydroquinoxalin-5-yl)-N-alkylsulfonamides as peripherally restricted N-methyl-D-aspartate receptor antagonists for the treatment of pain. Bioorg Med Chem Lett 17:4599-4603. (Pubitemid 47058939)
5. Di L and Kerns EH (2011) Methods for assessing blood brain barrier penetration in drug discovery, in ADME-Enabling Technologies for Drug Design and Development (Zhang D and Surapaneni S eds), John Wiley & Sons, New York, in press.
6. Di L, Kerns EH, and Carter GT (2008) Strategies to assess blood-brain barrier penetration. Expert Opin Drug Discov 3:677-687.
7. Elmquist WF and Sawchuk RJ (1997) Application of microdialysis in pharmacokinetic studies. Pharm Res 14:267-288. (Pubitemid 27160936)
8. Ertl P, Rohde B, and Selzer P (2000) Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. J Med Chem 43:3714-3717.
9. Fridén M, Bergström F, Wan H, Rehngren M, Ahlin G, Hammarlund-Udenaes M, and Bredberg U (2011) Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods. Drug Metab Dispos 39:353-362.
10. Fridén M, Ducrozet F, Middleton B, Antonsson M, Bredberg U, and Hammarlund-Udenaes M (2009a) Development of a high-throughput brain slice method for studying drug distribution in the central nervous system. Drug Metab Dispos 37:1226-1233.
11. Fridén M, Gupta A, Antonsson M, Bredberg U, and Hammarlund-Udenaes M (2007) In vitro methods for estimating unbound drug concentrations in the brain interstitial and intracellular fluids. Drug Metab Dispos 35:1711-1719. (Pubitemid 47296068)
12. Fridén M, Winiwarter S, Jerndal G, Bengtsson O, Wan H, Bredberg U, Hammarlund-Udenaes M, and Antonsson M (2009b) Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids. J Med Chem 52:6233-6243.
13. Fuller WA (1987) Measurement Error Models. John Wiley & Sons, New York.
14. Hammarlund-Udenaes M (2000) The use of microdialysis in CNS drug delivery studies. Pharmacokinetic perspectives and results with analgesics and antiepileptics. Adv Drug Deliv Rev 45:283-294.
15. Hammarlund-Udenaes M, Fridén M, Syvanen S, and Gupta A (2008) On the rate and extent of drug delivery to the brain. Pharm Res 25:1737-1750.
16. Hammarlund-Udenaes M, Paalzow LK, and de Lange EC (1997) Drug equilibration across the blood-brain barrier - pharmacokinetic considerations based on the microdialysis method. Pharm Res 14:128-134. (Pubitemid 27146353)
17. Janiszewski JS, Rogers KJ, Whalen KM, Cole MJ, Liston TE, Duchoslav E, and Fouda HG (2001) A high-capacity LC/MS system for the bioanalysis of samples generated from platebased metabolic screening. Anal Chem 73:1495-1501. (Pubitemid 32896206)
18. Jeffrey P and Summerfield SG (2007) Challenges for blood-brain barrier (BBB) screening. Xenobiotica 37:1135-1151. (Pubitemid 350041554)
19. Kakee A, Terasaki T, and Sugiyama Y (1996) Brain efflux index as a novel method of analyzing efflux transport at the blood-brain barrier. J Pharmacol Exp Ther 277:1550-1559. (Pubitemid 27167171)
20. Kalvass JC and Maurer TS (2002) Influence of nonspecific brain and plasma binding on CNS exposure: implications for rational drug discovery. Biopharm Drug Dispos 23:327-338. (Pubitemid 36124162)
21. Kerns EH and Di L (2008) Drug-Like Properties: Concepts, Structure Design and Methods: from ADME to Toxicity Optimization. Elsevier, London.
22. Kratochwil NA, Huber W, Müller F, Kansy M, and Gerber PR (2004) Predicting plasma protein binding of drugs - revisited. Curr Opin Drug Discov Devel 7:507-512. (Pubitemid 44383557)
23. Lin JH (2008) CSF as a surrogate for assessing CNS exposure: an industrial perspective. Curr Drug Metab 9:46-59.
24. Lipinski CA, Lombardo F, Dominy BW, and Feeney PJ (1997) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 23:3-25. (Pubitemid 27046991)
25. Liu X, Chen C, and Smith BJ (2008) Progress in brain penetration evaluation in drug discovery and development. J Pharmacol Exp Ther 325:349-356. (Pubitemid 351574780)
26. Liu X, Smith BJ, Chen C, Callegari E, Becker SL, Chen X, Cianfrogna J, Doran AC, Doran SD, Gibbs JP, et al. (2006) Evaluation of cerebrospinal fluid concentration and plasma free concentration as a surrogate measurement for brain free concentration. Drug Metab Dispos 34:1443-1447. (Pubitemid 44285383)
27. Liu X, Van Natta K, Yeo H, Vilenski O, Weller PE, Worboys PD, and Monshouwer M (2009) Unbound drug concentration in brain homogenate and cerebral spinal fluid at steady state as a surrogate for unbound concentration in brain interstitial fluid. Drug Metab Dispos 37:787-793.
28. Mano Y, Higuchi S, and Kamimura H (2002) Investigation of the high partition of YM992, a novel antidepressant, in rat brain - in vitro and in vivo evidence for the high binding in brain and the high permeability at the BBB. Biopharm Drug Dispos 23:351-360. (Pubitemid 36002134)
29. Maurer TS, Debartolo DB, Tess DA, and Scott DO (2005) Relationship between exposure and nonspecific binding of thirty-three central nervous system drugs in mice. Drug Metab Dispos 33:175-181. (Pubitemid 40023529)
30. Read KD and Braggio S (2010) Assessing brain free fraction in early drug discovery. Expert Opin Drug Metab Toxicol 6:337-344.
31. Shen DD, Artru AA, and Adkison KK (2004) Principles and applicability of CSF sampling for the assessment of CNS drug delivery and pharmacodynamics. Adv Drug Deliv Rev 56:1825-1857. (Pubitemid 39307054)
32. Smith DA, Di L, and Kerns EH (2010) The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery. Nat Rev Drug Discov 9:929-939.
33. Summerfield SG, Lucas AJ, Porter RA, Jeffrey P, Gunn RN, Read KR, Stevens AJ, Metcalf AC, Osuna MC, Kilford PJ, et al. (2008) Toward an improved prediction of human in vivo brain penetration. Xenobiotica 38:1518-1535.
34. Summerfield SG, Stevens AJ, Cutler L, del Carmen Osuna M, Hammond B, Tang SP, Hersey A, Spalding DJ, and Jeffrey P (2006) Improving the in vitro prediction of in vivo central nervous system penetration: integrating permeability, P-glycoprotein efflux, and free fractions in blood and brain. J Pharmacol Exp Ther 316:1282-1290. (Pubitemid 43345304)
35. Wan H, Rehngren M, Giordanetto F, Bergström F, and Tunek A (2007) High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery. J Med Chem 50:4606-4615. (Pubitemid 47463235)
36. Watson CJ, Venton BJ, and Kennedy RT (2006) In vivo measurements of neurotransmitters by microdialysis sampling. Anal Chem 78:1391-1399. (Pubitemid 43346271)
37. Whalen K, Gobey J, and Janiszewski J (2006) A centralized approach to tandem mass spectrometry method development for high-throughput ADME screening. Rapid Commun Mass Spectrom 20:1497-1503.